Luminar Media Group Inc., Provides Update on TherOZap™ Working Prototype

Toronto, Ontario, March 06, 2017 (GLOBE NEWSWIRE) -- Luminar Media Group, Inc., (Luminar, OTCMKTS: LRGR), reports that the development of the working prototype for the patent pending TherOZap™ is scheduled for completion prior to the end of March 2017.  A selection of features and optimal components have been finalized for the working prototype.  As previously reported Jenex expects to test the working prototype to determine its effectiveness at inactivating both the Zika and West Nile virus and potentially other mosquito borne diseases. Testing will be initiated by a world renowned scientific research lab upon completion of the working prototype.  

Luminar CEO, Chris Cook commented;

"As we approach the home stretch of product development, Luminar is looking forward to the next stage of the product development where we can focus on sales and marketing strategies."

Rob Fia, Jenex CEO commented:

 "We are pleased to have advanced the design process further with our TherOZap™ device and excited to finalize the working prototype."

Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.

About Jenex

Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX JEN. For more information visit: www.thejenexcorporation.com or www.therozap.com

About Luminar:

The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries. Luminar will bring this expertise to the TherOZap™ trade name and is developing a global marketing strategy.  Initial efforts will focus on launching its innovative therapy device in the United States with additional markets to follow closely. The company was started by entrepreneurs who can identify new tools to communicate with a target audience.  At Luminar, we embrace the challenge of the constantly evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm.

Forward-Looking Statements

This news release contains forward-looking statements about our business, or financial condition and prospects, that reflect our assumptions and beliefs based on information currently available. The Company can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this news release, words such as "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including risks discussed in the company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.

Luminar Media Group Investor Relations
Email: info@luminarinc.com
Website: www.gdee.rocks , http://www.luminarinc.com/
Source: Luminar Media Group, Inc.